Anaptysbio (ANAB) Share-based Compensation (2021 - 2025)
Anaptysbio's (ANAB) quarterly Share-based Compensation came in at $8.5 million in Q4 2025, up 3.93% YoY from $8.2 million in Q4 2024, and down 67.43% on a QoQ basis from $26.1 million in Q3 2025.
Anaptysbio (ANAB) Share-based Compensation (2021 - 2025) Analysis & Trends
Anaptysbio (ANAB) has 5 years of Share-based Compensation data on file, last reported at $8.5 million in Q4 2025.
- Quarterly Share-based Compensation rose 3.93% year-over-year to $8.5 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $26.9 million (down 18.69% YoY) and the FY2025 annual result came in at $36.5 million, up 7.2% from the prior year.
- Share-based Compensation declined to $8.5 million in Q4 2025, from $26.1 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $26.1 million in Q3 2025 to a low of -$20.7 million in Q4 2022.
- A 5-year average of $5.2 million and a median of $7.7 million in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation plunged 321.89% — and 2024, when it jumped 512.0%.
- Tracing ANAB's Share-based Compensation over 5 years: stood at $9.3 million in 2021, then slumped by 321.89% to -$20.7 million in 2022, then surged by 114.51% to $3.0 million in 2023, then surged by 172.8% to $8.2 million in 2024, then increased by 3.93% to $8.5 million in 2025.
- The last three Share-based Compensation figures came in at $8.5 million (Q4 2025), $26.1 million (Q3 2025), and -$7.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.51 Mn |
| Dec 31, 2025 | 8.51 Mn |
| Sep 30, 2025 | 26.12 Mn |
| Sep 30, 2025 | 26.12 Mn |
| Jun 30, 2025 | -7.72 Mn |
| Jun 30, 2025 | -7.72 Mn |
| Mar 31, 2025 | 9.17 Mn |
| Mar 31, 2025 | 9.17 Mn |
| Dec 31, 2024 | 8.18 Mn |
| Dec 31, 2024 | 8.18 Mn |
| Sep 30, 2024 | 18.36 Mn |
| Sep 30, 2024 | 18.36 Mn |
| Jun 30, 2024 | -2.63 Mn |
| Jun 30, 2024 | -2.63 Mn |
| Mar 31, 2024 | 10.13 Mn |
| Mar 31, 2024 | 10.13 Mn |
| Sep 30, 2023 | 3.00 Mn |
| Sep 30, 2023 | 3.00 Mn |
| Jun 30, 2023 | 2.90 Mn |
| Jun 30, 2023 | 2.90 Mn |